Cyclin-dependent kinase 5 (cdk5) has been implicated in Alzheimer's disease (AD) pathogenesis. Here, we demonstrate that overexpression of p25, an activator of cdk5, led to increased levels of BACE1 mRNA and protein in vitro and in vivo. A p25/cdk5 responsive region containing multiple sites for signal transducer and activator of transcription (STAT1/3) was identified in the BACE1 promoter. STAT3 interacts with the BACE1 promoter, and p25-overexpressing mice had elevated levels of pSTAT3 and BACE1, whereas cdk5-deficient mice had reduced levels. Furthermore, mice with a targeted mutation in the STAT3 cdk5 responsive site had lower levels of BACE1. Increased BACE levels in p25 overexpressing mice correlated with enhanced amyloidogenic processing that could be reversed by a cdk5 inhibitor. These data demonstrate a pathway by which p25/cdk5 increases the amyloidogenic processing of APP through STAT3-mediated transcriptional control of BACE1 that could have implications for AD pathogenesis.
INTRODUCTION
Cdk5 is a proline-directed serine/threonine kinase that is activated by association with its regulators p35 or p39 or their corresponding cleaved C-terminal fragments p25 or p29, respectively Tsai et al., 1994) . Several proteins with diverse functions have been identified as cdk5 substrates, including tau (Baumann et al., 1993; Kobayashi et al., 1993 ), b-catenin (Kesavapany et al., 2001 , Nudel (Sasaki et al., 2000) , FAK (Xie et al., 2003) , Synapsin 1 (Matsubara et al., 1996) , ErbB (Fu et al., 2001) , Retinoblastoma protein (Hamdane et al., 2005) , MEF2 (Gong et al., 2003) and STAT3 (Fu et al., 2004) . Most of these substrates are active in the central nervous system (CNS) and have been implicated in the regulation of physiological activities, such as microtubule and actin dynamics, transportation, cell adhesion, axon guidance, secretion and neuronal migration (reviewed in Dhavan and Tsai, 2001) . Cdk5 activation has also been demonstrated in nonneuronal tissues with a role in myogenesis, hematopoietic cell differentiation, spermatogenesis, and insulin secretion (Cruz and Tsai, 2004) .
AD is the most common form of dementia in the elderly. The disease is characterized neuropathologically by the accumulation and deposition of amyloid b-peptide (Ab) into neuritic plaques and by the formation of intracellular neurofibrillary tangles (NFT) containing hyperphosphorylated tau. Kinases such as cdk5 and glycogen synthase kinase-3 (GSK-3) significantly enhance tau hyperphosphorylation (Maccioni et al., 2001; Planel et al., 2002) and amyloid-b precursor protein (APP) processing in vivo (Phiel et al., 2003; Cruz et al., 2006; Rockenstein et al., 2007) , and they may be important therapeutic targets for AD treatment or prevention.
Plaque-associated Ab is generated following cleavage of APP by b site APP cleaving enzyme 1 (BACE1) (Vassar et al., 1999) and g-secretase (De Strooper et al., 1998; Edbauer et al., 2003) . BACE1 appears to be the only b-secretase responsible for Ab generation, as BACE1-deficient mice do not generate Ab (Luo et al., 2001) . BACE1 undergoes glycosylation, endosomal targeting, and activation by pro-peptide cleavage as it matures (Capell et al., 2000; Huse et al., 2000) , and several pathways impact the level of BACE1 in the brain including phosphorylation at Ser498 by casein kinase 1 (Walter et al., 2001) , lysosomal targeting (Koh et al., 2005) , and ubiquitin-mediated degradation . BACE1 is responsive to various physiological and pathological situations including ischemia (Wen et al., 2004) , hypoxia , cytokines (Hong et al., 2003) , oxidative stress (Tamagno et al., 2005) , and cholesterol content (Ghribi, 2006) . The level and activity of BACE1 protein is increased in AD patient brains (Fukumoto et al., 2002; Stockley et al., 2006) , possibly due to elevation of BACE around plaques (Zhao et al., 2007) .
The promoter of the BACE1 gene has been characterized Sambamurti et al., 2004) , and specific regulatory domains have been located by deletion analysis . The promoter has characteristics common to both constitutive and inducible expression and contains both negative and positive domains, separated from the transcription seat by a long, neutral domain . In addition, putative transcription factor sites such as those for SP1 and STAT6 have been identified. An active SP1 site is over 1kb upstream of the +1 transcription start (TSS), indicating the possibility of other active, distal sites of gene regulation . Notably, it has been determined that the BACE1 promoter is differentially regulated according to cell type and that its regulation differs from other members of the BACE family, such as BACE2 ).
In the current study, we investigated the role of p25/cdk5 in the regulation of BACE1 and the generation of Ab. We demonstrate that p25 overexpression in mice leads to increased cdk5 activity that correlates with increased BACE1 and Ab levels. Conversely, BACE1 and Ab levels were reduced following administration of a cdk5 inhibitor. The identification of a functional, p25/cdk5 responsive element in the promoter of the BACE1 gene indicates that BACE1 can be regulated by cdk5 through transcriptional control, with STAT3 being a likely mediator. We therefore propose a signaling pathway by which BACE1 is regulated in response to cdk5 activity in vivo. These findings identify one mechanism by which aberrant p25/cdk5 activity could enhance Ab accumulation and suggest that inhibitors of cdk5 are candidates for therapeutic development.
RESULTS

Elevated p25
Correlates with BACE1 Accumulation and Enhanced APP Processing In Vitro To examine the effect of p25 on BACE and APP metabolism, SH-SY5Y cells stably transfected with a tetracycline-inducible p25 construct (p25), or empty vector (mock) (Hamdane et al., 2003 ; Figure 1A ), were assessed. Both mock and p25-transfected cells had high levels of cdk5 but lacked p35 protein. The level of BACE1 protein was greatly enhanced in induced p25 cells. BACE1 cleaves APP to generate a secreted APPb fragment and a membrane bound carboxy-terminal fragment (C99, b-CTF). b cleavage of APP was significantly enhanced as shown by accumulation of the b-CTF in the induced p25 cells. Compared with the mock cells, the levels of full-length APP (APP fl) and a-CTF (C83) were unchanged, although a slight shift in mobility was seen for both in the p25-induced cells.
To assess whether BACE1 activity was enhanced, a FRETbased activity assay ( Figure 1B ) was performed. As a positive control, BACE1 overexpressing HEK293 cells (B1) were included. Each sample was treated with a specific BACE1 inhibitor (EMD 565788; Stachel et al., 2004) . All samples showed similar residual activity, presumably due to the activity of nonspecific, contaminating acidic proteases. Our data showed that BACE1 activity was significantly enhanced in both the positive control and the p25-transfected cells. To assess whether increased BACE1 activity resulted in increased Ab production, endogenous Ab40 and 42 levels were measured in conditioned media from the cultured cells ( Figure 1C ). The levels of both Ab40 and 42 were significantly increased (p < 0.001) in media from induced p25 cells. These data demonstrate that endogenous BACE1 in p25 transfected cells was active and had enhanced activity toward its endogenous physiological substrate, APP.
To examine why BACE1 accumulates in response to elevated p25/cdk5 activity, we assessed the level of BACE1 mRNA and protein in p25-transfected cells. Quantitative real-time PCR (qPCR) showed that the level of BACE1 mRNA from p25-transfected SH-SY5Y cells was $6-fold higher than mock cells after normalization to actin mRNA ( Figure 1D ). Different probes recognizing 5 0 or 3 0 BACE1 mRNA showed a similar fold of induction (data not shown).
Identification of cdk5 Responsive Sites in the BACE1 Promoter
To examine whether the increase in BACE1 mRNA was due to an effect on BACE1 synthesis through upregulation of its promoter activity, two sets of promoter constructs were examined. The first was a stable transfected, rat pheochromocytoma (PC12) cell line expressing 3.2 kb of the BACE1 promoter regulating the expression of the reporter gene, firefly luciferase ( Figure 2A ). Levels of reporter protein were assessed in cells transfected with p25, cdk5, or empty vector. Renilla luciferase or GFP control plasmids were cotransfected to normalize for transfection efficiency. As expected, transfection of cdk5 alone without activator had no significant effect on the regulation of the BACE promoter activity. Transfection with p25 led to 1.7-fold increase in reporter gene transcription, compared with vector alone. To identify which region of the promoter was responding to p25/cdk5, two deletion constructs, BACE1P6 (À1056/+364, +1 being the transcription start site) and BACE1P8 (À327/+364), containing portions of the BACE1 promoter regulating expression of the reporter CAT, were transiently cotransfected with p25-GFP or empty vector into N2a cells ( Figure 2B ). After normalization, the level of CAT generated from the BACE1P6 construct was $2-fold higher in p25-transfected cells than in mock-transfected cells. Levels of CAT from the BACE1P8 construct were not significantly different from mock-transfected cells, and the difference between these two constructs suggested that regions present in BACE1P6, but not BACE1P8, were responsive to p25, leading to increased activity of the BACE1 promoter ( Figure 2B ). Mapping of the responsive region on the promoter revealed numerous potential transcriptional regulation sites for STAT1/3 and MEF2 ( Figure 2C ).
Confirmation of the Role of STAT3 in the Regulation of BACE1 Transcription Both STAT3 and MEF2 are cdk5 responsive transcription factors known to regulate transcription of numerous target genes (Gong et al., 2003; Fu et al., 2004) . However, phosphorylation of MEF2 by cdk5 suppresses its transcription activity (Gong et al., 2003) , and we did not examine its role in BACE1 transcription further. Cytoplasmic STAT3 is phosphorylated at the serine 727 site by several kinases including cdk5 (Fu et al., 2004 ). Phosphorylation at this site induces dimer formation, leading to phosphorylation at multiple tyrosine sites, including tyrosine 705. This then leads to translocation of STAT3 to the nucleus (Brierley and Fish, 2005) . As experiments in Figure 3 focused on the nuclear association of STAT3 with the BACE promoter, pSTAT3(Y705) rather than pSTAT3(S727) was monitored in these experiments. To confirm that enhanced p25/cdk5 led to increased levels of pSTAT3(Y705), induced p25 cells were examined. As expected, p25 cells showed higher levels of BACE1 compared to mock-transfected cells, and this correlated with increased pSTAT3(Y705) ( Figure 3A ). We then examined whether BACE1 was upregulated by interferon-a (INF-a)-a cytokine that upregulates phosphorylation of STAT3 at tyr705 (reviewed in Brierley and Fish, 2005) . SH-SY5Y cells treated with INF-a demonstrated enhanced levels of BACE1, and this correlated with increased pSTAT3(Y705) ( Figure 3B ). To demonstrate that the cytokine was mediating its effect on BACE1 through pSTAT3, an inhibitor of STAT3 dimerization (EMD 573095) was added to the culture medium. The inhibitor reduced levels of pSTAT3(Y705), as well as BACE1 in both control cells, and cells induced with . Graphical representation of the data is shown in Figure 3C . To examine whether STAT3 binds BACE1 promoter DNA, chromatin immunoprecipitation (ChIP) analysis was performed ( Figure 3D ). DNA from SH-SY5Y cells that had been treated with vehicle or with INF-a was crosslinked and mechanically sheared. Chromatin was then immunoprecipitated with a STAT3 antibody that recognizes total STAT3 and was subjected to PCR using primers from two regions of the BACE1 promoter-a region upstream that contains multiple STAT1/3 sites (BACE1-U primer set) and a region downstream that contains a single STAT1/3 site (BACE1-D primer set). Different primers recognizing the promoter of the interleukin-8 gene (IL-8), a known STAT3 target gene (Gharavi et al., 2007) , were used as a positive (A) Schematic of the 3.2kb BACE1 promoter/luciferase fusion clone, indicating the position of +1 transcription start site. PC12 cells, stably transfected with the BACE1-pGL4.14 construct, were transiently transfected with a p25-GFP expression construct, a cdk5 expression construct, or mock vector. P25-GFP overexpression increased activity of the BACE1 promoter as determined by firefly luciferase activity. All cells were cotransfected with pRL-SV40 renilla luciferase control vector. Cdk5 overexpression without activator did not significantly affect activity of the BACE1 promoter. Overexpression of p25-GFP and cdk5 did not result in significant toxicity as determined by LDH assay (data not shown).
(B) Schematic of the BACE1P6 and BACE1P8 CAT fusion clones, indicating the position of +1 transcription start site. Normalized CAT levels in N2a cells transiently transfected with p25/GFP or mock vector and cotransfected with promoter constructs P6/CAT or P8/CAT. Levels of CAT were normalized to cotransfected GFP levels, which were similar among all groups. Data show n = 3 wells per cell group. Transfections and assays were repeated in triplicate with essentially similar results. **p < 0.01. control (data not shown). The negative control was chromatin incubated without STAT3 antibody. Figure 3D shows that a BACE1 PCR product was only generated from DNA incubated with the STAT3 antibody. Both primer sets amplified a band of the expected size (188-197 bp) in chromatin incubated with antibody, and in the total DNA (''input'') positive control. To further confirm and quantify these results, qPCR was performed on the same samples using the BACE1-U primer set ( Figure 3E ), BACE1-D primer set, and the IL-8 primer set (data not shown). Samples that were incubated without STAT3 antibody failed to generate amplimers. Vehicle-treated cells showed a lower level of enrichment following IP with the STAT3 antibody compared to $12-fold increase in cells induced with INF-a. Both primer sets for BACE1 showed a similar level of amplification when compared by qPCR (data not shown), indicating that both the cluster and single STAT1/3 sites are targeted by STAT3. These data support the deletion analysis, indicating that STAT3 and the BACE1 promoter show a physical interaction under physiological conditions and that induction of pSTAT3 by INF-a significantly enhanced the association of STAT3 with BACE1 promoter DNA.
Elevated p25/cdk5 Activity Leads to Hyperphosphorylation of STAT3 and Enhanced BACE1 In Vivo
To confirm the effect of p25/cdk5 on BACE1 and APP processing in vivo, we examined mice that overexpress human p25 (Ahlijanian et al., 2000) . STAT3 phosphorylation was examined in homozygous p25 mice at 4 days of age, compared with strain-matched, nontransgenic (Ntg) mice of the same age in four different sets of mice. This age was chosen because overall phosphorylation levels are high in neonatal animals (MawalDewan et al., 1994) . P25 mice showed enhanced levels of pTau(S235), a site used to monitor cdk5 activity, compared to Ntg mice. We then examined p25 and Ntg mice for pSTAT3. pSTAT3(S727) was significantly elevated when normalized to levels of total STAT3 protein in all sets of p25 mice. The level of BACE1 was significantly elevated in p25 mice compared to Ntg controls in two sets of mice, and a trend to increase was seen in the other two sets. A representative set is shown in Figure 4A , with Ntg and p25 mice (n = 10-11).
Loss of cdk5 Activity Reduces pSTAT3 and BACE1 Levels We next examined whether loss of cdk5 activity reduced levels of BACE1 in vivo, through the examination of cdk5-deficient mice (Ohshima et al., 1996) . As cdk5-deficient mice are not viable, embryos were taken at E16.5 for analysis. Brain lysate from cdk5-deficient embryos showed $30% reduction in BACE1 levels and $70% reduction in pSTAT3(S727) levels ( Figure 4B ) compared to wild-type controls.
Targeted Mutation of pSTAT3(S727) Leads to Reduced BACE1
To further confirm that phosphorylation of STAT3 impacts BACE1 synthesis, we examined a line of mice in which the serine site of STAT3 at position Ser727 was substituted for alanine (SA allele) (Wen and Darnell, 1997; Shen et al., 2004 ; Figure 4C ). Homozygous SA/SA mice are viable and phenotypically normal. Brain tissue from mice at 4 days of age was extracted, and the level of BACE1 was compared with age, bodyweight, and strain-matched WT controls. The mean level of BACE1 in STAT3 SA mice (n = 5) was reduced to 71% of WT levels (n = 6; Figure 4C ). To test whether BACE levels were significantly different between targeted and WT mice, ANOVA analysis was (E) ChIP samples were also examined by qPCR using the BACE1-U primers, with the relative expression levels graphically represented following normalization. Vehicle treated cells immunoprecipitated with STAT3 antibody expression was set to 1. **p < 0.01, ***p < 0.001.
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performed. The results showed that the level of BACE1 was significantly different between WT and targeted mice (p < 0.05; see Table S1 available online for statistical analysis).
An Inhibitor of cdk5 Reduced Levels of pSTAT(S727) and BACE1 In Vivo The brain-permeable cdk5 inhibitor CP-681301 (CP, L.-F.L., Pfizer, unpublished data) was administered to Ntg or p25 mice by subcutaneous injection. Inhibition of cdk5 was monitored through phosphorylation of tau at S235. CP-681301 treatment of young Ntg mice (n = 5-6) led to significant reduction of BACE1 mRNA and protein that correlated with reduced pSTAT3(S727) ( Figure 5A ). Young p25 mice administered the inhibitor under similar conditions also showed a significant decrease in BACE1, as well as Ab40/42 (two sets tested); a representative set is shown in Figure 5B (see also Table S2 ; n = 6-7). Ab is turned over very rapidly in vivo. To confirm that the reduction of Ab seen with inhibitor did not reflect overall reduced metabolism due to drug toxicity, we examined the levels of p35, a protein with a turnover time similar to Ab (less than 1 hr) as well as tubulin (a long-lived protein). Levels of p35 were not significantly different between vehicle and CP treated mice (data not shown), suggesting that the reduction of Ab was due to effects on APP processing and not overall toxicity. In most sets of inhibitor-treated animals, reduced APP levels were observed; however, the decrease did not reach statistical significance consistently (data not shown).
BACE1 Synthesis and APP Processing Is Also Modulated by cdk5 in Adult Mice
ELISA analysis showed that the levels of both Ab40 (p < 0.01) and Ab42 (p < 0.05) were significantly increased in adult p25 mice compared to littermate Ntg (n = 7-9; Figure 6A ; Table S3 ). Similarly, both protein and mRNA levels of BACE1 were significantly higher than in the Ntg control mice (p < 0.001; Figure 6A ). Four sets of adult Ntg mice (n = 5 per group) were administered the cdk5 inhibitor CP-681301 for 2 days. In all four sets, CP-681301 treatment reduced Ab and BACE1 levels significantly ( Figure 6B ; see Table S4 for ELISA data).
As the level of murine b-CTF is very low in Ntg mice, we examined the effect of enhanced cdk5 activity on human APP in double-transgenic mice that express both p25 and mutant human APP (Figure 7) . The level of full-length APP was comparable between p25/APP and APP littermates, but the level of b-CTF (C99) was significantly elevated relative to a-CTF (C83) in p25/APP mice ( Figure 7A ). Consistent with this being a predominantly b-secretase effect, the level of sAPPb was significantly elevated in p25/APP mice. BACE1 was also significantly increased in p25/ APPmice, compared with APP mice. The level of sAPPb was significantly increased, but the level of sAPPa was not significantly changed ( Figure 7B ). Amyloid load was assessed in the p25/APP mice and their APP littermates to determine if p25-mediated elevation of Ab accelerated the formation of amyloid plaques. Although plaques were detected in all mice, amyloid load was highly variable and no overt difference was observed (data not shown). ELISA data revealed a trend to increase in both soluble and formic acid extracted (total) Ab in the double-transgenic p25/APP mice (n = 6) relative to APP littermates (n = 6), but the increase was not statistically significant (see Table S5 for ELISA values).
DISCUSSION
We have shown that BACE1 is transcriptionally upregulated in response to enhanced cdk5 activity mediated by p25. The cdk5 target, STAT3, binds BACE1 promoter DNA, and the level of pSTAT3 correlates with the level of BACE1 both in vivo and in vitro, suggesting that STAT signaling is one pathway by which transcriptional control can be mediated. BACE1 showed increased activity toward its substrate, APP, leading to increased levels of Ab40 and 42 in p25 mice, similar to that reported by Cruz et al. (2006) for an inducible p25 mouse line. Pharmacological inhibition of cdk5 reduced the level of BACE1, and Ab peptides making inhibition of cdk5 a valid target for AD therapeutics.
The cdk5-reponsive region of the BACE1 promoter contains numerous sites, including sites for STAT1/3 and MEF2, that are both transcriptional factors known to be physiological substrates of p25/cdk5 in vivo and in cell culture systems (Fu et al., 2004 ; (S235), BACE1, STAT3, pSTAT3(S727), and tubulin (loading control) in brain lysate from Ntg and p25 mice (n = 10-11 for each group, two mice shown). BACE1 and pSTAT3/STAT3 levels were significantly higher in p25 mice compared with Ntg mice, as shown in the scatterplots.
(B) Immunoblot analysis of cdk5-deficient mice compared with wild-type mice. Reduced levels of BACE1 and pSTAT3(S727) were observed in cdk5 null mice (KO), compared with wild-type control mice (WT); tubulin is shown as loading control. Several embryonic (day 16.5) brains were pooled to generate lysate. (C) Immunoblot analysis of BACE1 levels in mice with targeted ablation of the cdk5 responsive site at STAT3(727) (SA). STAT3 SA mice showed no detectable pSTAT3(S727). BACE1 was significantly reduced in homozygous SA mice at 4 days of age compared to strain and age matched controls (n = 5 for SA mice, n = 6 for WT, two mice for each shown). *p < 0.05. Ge et al., 2004; Gong et al., 2003) . In addition to a previously reported STAT6 binding site at À931 , STAT1/3 sites were identified at positions À932, À931, À865, À845, À844, À829, and À439, and a cluster of five sites were identified between À901 and À897. Furthermore, MEF2 sites were identified at À901, À899, À898, and À442 . These sites are all present in the BACE1P6 promoter region but absent from BACE1P8, suggesting that cdk5 may be mediating its effect on BACE1 transcription through one or both of these factors . Between the transcription initiation site and the physiological translation initiation codon of the human BACE1 gene, there are six upstream ATGs that could serve as the translation initiation codons for five potential ORFs. These mORFs have a negative effect on BACE1 protein translation due to leaky scanning (Lammich et al., 2004; Zhou and Song, 2006) . P25/cdk5 activation may also negatively regulate transcription through inhibitory factors such as MEF2, and it is likely that several factors influence the spatial and temporal pattern of target gene transcription during development and in the diseased brain. STAT1 and 3 sites are also present in many other gene promoters, including the human and mouse APP promoter (Song and Lahiri, 1998) . Enhanced amyloidogenic processing could therefore also be the result of APP upregulation. However, the level of full-length APP was not significantly altered by increased p25, either in vitro or in p25 transgenic mice, suggesting that in the systems studied, p25/cdk5-mediated effects act primarily on BACE1 rather than APP.
Most reports indicate that BACE1 mRNA does not increase in the AD brain (Holsinger et al., 2002; Matsui et al., 2007; Preece et al., 2003; Yasojima et al., 2001 ) whereas BACE protein/activity does increase (Fukumoto et al., 2002; Harada et al., 2006; Holsinger et al., 2002; Stockley et al., 2006; Tyler et al., 2002; Yang et al., 2003) . Several mechanisms have been suggested to account for the increase in BACE1 protein levels including posttranscriptional (Lammich et al., 2004; Zohar et al., 2005) , posttranslational (Walter et al., 2001) , or turnover effects . BACE1 mRNA levels have, however, been shown to be altered in regions with high plaque density from human AD brain with short postmortem interval (PMI) (Li et al., 2004) , but not longer PMI (Matsui et al., 2007) suggesting that in human brain, postmortem mRNA degradation may confound interpretation. This does not, however, explain the increase in BACE1 protein, but not BACE1 mRNA observed in plaque-forming mice (Zhao et al., 2007) , leaving the issue of the mechanism by which BACE1 increases in the AD brain unresolved.
The impact of p25/cdk5 on the pathogenesis of Alzheimer's disease is speculative. Although published data suggests that cdk5 activity is increased in AD brain (Lee et al., 1999) , the involvement of p25 remains controversial (Patrick et al., 1999; Tandon et al., 2003; Tseng et al., 2002) . Cdk5-mediated transcriptional upregulation of BACE could be envisioned to initiate or exacerbate AD pathogenesis in certain situations, however. Increased production of p25 and enhancement of cdk5 activity has been shown to occur in rodent models of ischemia Wen et al., 2007) , and hypoxia due to hypoperfusion is a significant risk factor for long-term susceptibility to AD (Kalaria, 2000; Kalaria and Hedera, 1995) . Ischemia in rodents has been shown to increase amyloidogenic processing of APP (Saido et al., 1994; Wen et al., 2004; Yokota et al., 1996) , and AD pathology is increased in patients with coexisting evidence of cerebral infarcts (Nagy et al., 1997; Snowdon et al., 1997) . Interestingly, pSTAT3 is one of several transcription factors upregulated by ischemia-induced hypoxia (Justicia et al., 2000) , and hypoxia has been shown to upregulate BACE1 transcription through hypoxia inducing factor 1-alpha (HIF1-a) . It is thus feasible that hypoxia-induced production of p25 and subsequent enhanced activity of cdk5 leads to local upregulation of BACE1 transcription, Ab production, and initiation or exacerbation of a pathological cascade resulting in AD.
Several substrates in addition to BACE1 are likely to be impacted by enhanced p25/cdk5 activity that could also result in increased amyloidogenic processing in vivo. Systems involved in trafficking that are known to be targets of cdk5 such as cytoskeleton proteins (tau, amphiphysin I, and dynamin I) or vesicles regulating endocytosis or exocytosis (Tomizawa et al., 2003; Xin et al., 2004) may alter trafficking and recycling of BACE1 leading to accumulation in early endosomes-a compartment favorable to increased amyloidogenic processing. Phosphorylation of BACE1 itself also results in its redistribution, as it has been previously reported that phosphorylation at the S498 site by CK1 alters BACE1 trafficking or sorting (Pastorino et al., 2002; Walter et al., 2001) . Although there are two potential cdk5 consensus (B) Three groups of young (5-day-old) mice were analyzed for Ab and BACE1 levels: Ntg mice treated with vehicle (Veh; n = 7), p25 mice treated with vehicle (p25/veh; n = 7), and p25 mice treated with CP-681301 (p25/ CP; n = 6). Ab40 and 42 levels were elevated in p25 mice relative to Ntg mice. Administration of CP-681301 to p25 mice significantly reduced both peptides (p < 0.01). BACE1 was elevated in p25 mice relative to Ntg mice but was significantly reduced by CP-681301. The relative activity of cdk5 was shown by phosphorylation of Tau at the S235 site. Total tau levels indicated that equivalent levels of protein were loaded. All results were analyzed with Student's t test, *p < 0.05, **p < 0.01.
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Regulation of b-Secretase by p25/cdk5 sites in BACE1 in the ectodomain, the localization (lumen compartment) makes it unlikely that BACE1 is a direct target for cdk5-mediated posttranslational modification. Another substrate mediating the cdk5 effect on Ab production could be APP itself as cdk5-directed phosphorylation of APP at the T668 site has been proposed to alter its accessibility to secretases leading to enhanced Ab production . However, recent gene-targeting experiments suggest that the T668 site is not involved in Ab generation in vivo (Sano et al., 2006) .
Our data demonstrate that in both young and old mice, elevated p25/cdk5 increases Ab production through an increase in BACE1, and this effect can be reversed using a pharmacological inhibitor. While STAT3 is a potent inducer of BACE1 transcription, the mechanism of induction is probably not limited to transcriptional regulation via pSTAT3. Overall, given that p25/ cdk5 significantly enhances Ab production in vivo, inhibition of p25/cdk5 may be an appealing therapeutic approach for the treatment or prevention of AD.
EXPERIMENTAL PROCEDURES Animals P25 mice were the generous gift of Pfizer (Ahlijanian et al., 2000) and are available as cryopreserved stock from The Jackson Laboratory, Bar Harbor, ME. The p25 mice used were homozygous, on an FVB background. Ntg mice were age, strain, and sex matched. Some experiments were repeated using hemizygous p25 mice and Ntg littermates. All animals were maintained and killed according to National Institutes of Health and IACUC guidelines. P25 mice were crossed to a mutant APP line (line Tg2576 [Hsiao et al., 1996] ). Hemizygous p25/APP and APP littermates at 10-12 months of age were examined. Mice lacking the p727 site in STAT3 (SA mice) were homozygous for the targeted mutation (kind gift of Dr. David Levy, NYU). Controls were age, strain, and size matched C57Bl/6 mice.
Tissue Culture P25 transfected SH-SY5Y cells under the control of the tetracycline-regulated mammalian expression T-Rex system (Invitrogen, Carlsbad, CA) were the kind gift of Dr. Luc Bué e (Hamdane et al., 2005) . For induction of p25 expression, cells were maintained in medium with tetracycline at 1 mg/ml. SH-SY5Y or N2a cells were grown in DMEM supplemented with 10% fetal calf serum and appropriate antibiotics (Invitrogen) in a 5% CO 2 humidified incubator at 37 C. Medium was replenished every 3 days. Transfections were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. Flag-GFP was cotransfected to allow normalization in the promoter-deletion experiments. SH-SY5Y cells were plated at 80% density, then washed twice with PBS prior to incubating them in serum-free media overnight. The following day, cells were washed in PBS, placed in fresh serum-free medium, and treated with either vehicle (PBS) or 235 mM STAT3 inhibitor/PBS (EMD Biosciences 573096, Gibstown, NJ) for 1 hr (Turkson et al., 2001) . After 1 hr of inhibitor or vehicle pretreatment, 1000 U/ml of IFN-a was added for 30 min. Following a 3.5 hr washout period, cells were harvested for biochemical analysis.
Immunoblot Analysis
Mice were sacrificed and the brains were immediately removed, dissected, and kept on dry ice. Hemibrains were weighed and homogenized without thawing in 53 RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF, 10 ml/ml protease inhibitor mix). Cultured cells were similarly lysed using RIPA buffer. Samples were centrifuged for 10 min at 20,000 3 g at 4 C. A protein assay was performed, and the samples were diluted in O+ buffer (62.5 mM Tris-HCl [pH 6.8], 10% (w/v) glycerol, 5% 2-mercaptoethanol, 2.3% SDS, 1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF, 10 ml/ml protease inhibitor mix) and incubated at 85 C for 10 min. Depending on the primary antibody used, 5-20 mg of protein was analyzed following electorophoresis on SDS-PAGE and transferred onto 0.2 mm nitrocellulose membranes (Whatman, Florham Park, NJ). Immunoblots were blocked, incubated with appropriate primary and secondary antibody dilutions (Jackson Immunoresearch, West Grove, PA), and treated using chemiluminescent fluid (Supersignal WestPico, Pierce, Rockford, IL). The signal was viewed using the Fujifilm LAS-3000 digital imaging system and Image Gauge software (Fujifilm, Stamford, CT).
Ab ELISA Soluble murine or human Ab1-40 and 1-42 from a hemibrain region including cortex and hippocampus was assessed using antibodies Abx-40 (JRF/ cAb40) and Abx-42 (JRF/cAb42/26) for capture; JRF/AbN-25 (human) JRF/ rAb1-15/2 for detection (gifts of Dr. Sonia Jung, Centocor R&D, Radnor, PA), as described previously (Schmidt et al., 2005a (Schmidt et al., , 2005b . Older p25 or Ntg mice between 18 and 22 months of age and juvenile mice between 4 and 6 days of age were used. Several sets of mice were assessed for each experiment.
Cdk5 Inhibitor Treatment CP-681301 (L.-F.L., unpublished data, gift of Dr. Lit-Fui Lau, Pfizer) at a concentration of 5.8 mg/ml in 30% hydroxypropyl-beta-cyclodextrin (Sigma, St. Louis, MO) or vehicle was injected subcutaneously at 100 ml/day once (neonates) or twice, 24 hr apart (adult mice). All mice became lethargic immediately after treatment and were sacrificed 4 hr after final administration.
Antibodies
For cdk5, anti-cdk5 (C-8) and anti-p35/25 (C-19) were used (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-human Ab1-17 for human sAPPa (6E10) and anti-sAPPb were purchased from Signet Laboratories, Deadham, MA. Monoclonal anti-BACE1 (3D5) was provided by Dr. Robert Vassar; polyclonal anti-BACE1 antibodies 7520 and 7523 were provided by Dr. Christian Haass. Full-length APP/CTFs were detected with antibody C1/6.1 that recognizes a C-terminal epitope in APP (provided by Dr. Paul Mathews). Anti-STAT3 (which recognizes all forms of STAT3), pSTAT3(S727), and pSTAT3(Y705) were purchased from Cell Signaling Technology, Danvers, MA. Total tau was detected with either Tau T57120 (monoclonal, BD Transduction Laboratories, San Jose, CA), or Tau A0024 (polyclonal, Dako Cytomation, Carpinteria, CA). MC6 (pTauS235) was provided by Dr. Peter Davies (Albert Einstein, NY). b-actin, a-, or b-tubulin were purchased from Sigma.
BACE1 Enzyme Assay
A FRET-based assay, using the substrate H-RE(EDANS)EVNLDAEFK(DAB-CYL)R-OH was performed according to the manufacturer's instruction (EMD Biosciences). Typically, the fluorescent EDANS molecule in the EDANS-XXX-DABCYL complex is quenched by the close proximity of the DABCYL molecule. In the assay, cellular BACE1 specifically cleaves the fluorogenic substrate, which then emits a measurable fluorescent signal. Briefly, cells were plated until they were 70% confluent. Cells were then lysed using the supplied buffer. Cell lysate (10 ml) was combined with the reaction buffer mix containing 10 mM of the fluorescent substrate and was loaded on an opaque plate, maintained at 37 C, and monitored every 20 min (Ex = 350 nm, Em = 490 nm; Wallac Victor2 1420, Perkin-Elmer, Shelton, CT). The reaction was carried out in the presence or absence of a specific BACE1 inhibitor (EMD 565788, 1 mM; Stachel et al., 2004) . HEK293 cells transfected with BACE1 were used as a positive control for this study.
Quantitative RT-PCR
Reverse transcription was performed on 1 mg of total RNA using the SuperScript III, first-strand SuperMix (Invitrogen) for qRT-PCR. Ten nanograms of cDNA was used in each PCR reaction. Quantitative PCR (qPCR) was performed by monitoring in real time, the increase in fluorescence of the iQ SYBR Green dye (Bio-Rad) on a Bio-Rad iQ5 detector system (Bio-Rad) according to the manufacturer's instructions. A standard curve was included in all experiments to monitor PCR efficiency. Each PCR was carried out in triplicate with 25 ml of the iQ SYBR Green Supermix (Bio-Rad). To exclude nonspecific contamination by products such as primer dimers, a melting curve analysis was applied to all the final PCR products following the cycling protocols. The level of human BACE1 mRNA was analyzed with two independent sets of primers, from the 5 0 end (5 0 -TGA TCA TTG TGC GGG TGG Stable Transfection of PC12 Cells with BACE1 Reporter Constructs PC12 cells were transfected with a pGL4.14 (Promega) vector containing a firefly luciferase reporter gene under the control of a 3.3 kb fragment of the BACE1 promoter region, spanning from À2975 to +364, and a hygromycin resistance gene. Three days posttransfection, selection with 200 mg/ml hygromycin began and continued for approximately one month until colonies developed in the culture plate. Twenty-four colonies were isolated and grown with continued hygromycin selection until sufficient cells were available for use. One thousand cells derived from each colony were subjected to a firefly luciferase assay (Promega), resulting in a range of baseline activities (data not shown). Based on relative activity, three stable PC12 clones were selected, representing median, low, and high levels of baseline luciferase activity. These cells were then transfected with a p25-GFP expression vector, or a cdk5 expression vector together with a renilla luciferase-containing pRLSV40 plasmid (Promega) as an internal control. Mock transfections contained the renilla plasmid only. Two days following transfection with the expression vectors, activities of both the stably transfected firefly luciferase and the transiently transfected renilla luciferase were measured using a Dual-Glo luciferase detection kit, as per manufacturer's instructions (Promega). The results of p25-GFP and cdk5 overexpression in all three stable PC12 lines were found to be very similar, so these data were combined and analyzed together as a single experiment.
Promoter Analysis
Three-six separate wells of N2a cells transfected with BACE1P6 or BACE1P8, with or without p25/GFP or vector were analyzed for CAT activity by ELISA as described previously . Data were expressed as CAT activity normalized to cotransfected GFP or renilla luciferase expression levels. To identify potential binding sites for the cdk5-associated transcription factors STAT1/3 and MEF2 in the BACE1 5 0 -flanking region, the TESS and Mat Inspector utilities were used to probe 1 kb of BACE1 promoter sequence.
Chromatin Immunoprecipitation Analysis
ChIP analysis was performed according to manufacturer's instruction using the ChIP-IT Express Kit (Active Motif, Carlsbad, CA). Briefly, SH-SY5Y cells at 80% confluency were treated with vehicle or IFN-a (1000 U/ml for 30 min), washed with PBS, crosslinked with 1% formaldehyde, and sheared by sonication to less than 500 bp fragments. The sheared chromatin was immunoprecipitated with total STAT3 antibody (Cell Signaling Technology). DNA crosslinking was reversed overnight, and PCR was then performed with primer pairs recognizing two different regions of the BACE1 promoter. Primer pair BACE1-U amplified a region containing multiple STAT3 binding sites (À957/ À760) (primer BACE1 (B) The level of a-secretase-cleaved sAPPa fragments were unchanged in p25/ APP mice compared to APP controls, but the fragments generated by BACE1 cleavage (sAPPb) were significantly increased in p25/APP mice compared to controls. BACE1 was also increased in the double-transgenic mice. b-actin was used as a loading control (n = 7 p25/APP, n = 6 APP, two mice of each group shown). (C) Scatterplots of sAPPb and BACE1 levels (values are normalized to APP group average = 1) were significantly higher (p < 0.05) in the p25/APP mice than the single transgenic group. *p < 0.05.
